Close Menu

NEW YORK (GenomeWeb) – With one test for guiding the choice of therapies for advanced prostate cancer slated to launch this year, research continues to paint a complex picture of the molecular determinants of drug response in this setting, raising questions for how the commercial testing landscape might evolve in the future.

New data published last month supports the potential for a simple droplet PCR-based method that interrogates a different marker than most tests have so far — androgen receptor copy number variation rather than expression of the AR-v7 splice variant.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.